Compositions for detecting IS1081 based on CRISPR / Cas system and methods and kits for diagnosing bovine tuberculosis using the same

The CRISPR/Cas12a system with IS1081-specific primers and probes provides a rapid and accurate method for detecting Mycobacterium bovis, addressing the inefficiencies of existing bovine tuberculosis diagnostics by ensuring high sensitivity and specificity.

KR103041948B1Active Publication Date: 2026-11-10NATIONAL INSTITUTE OF ENVIRONMENTAL RESEARCH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240073722
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-06-07
Filing Date
2024-06-05
Publication Date
2026-11-10
Estimated Expiration
2044-06-05

AI Technical Summary

Technical Problem

Current diagnostic methods for bovine tuberculosis, such as PCR, require Biosafety Level 3 facilities and are time-consuming, while skin tests and gamma interferon assays lack sensitivity and specificity, necessitating a more efficient and accurate detection method.

Method used

A CRISPR/Cas12a-based system using primers for IS1081 gene amplification, guide RNA (gRNA) specific to IS1081, Cas12a protein, and single-stranded DNA (ssDNA) probe for molecular detection of Mycobacterium bovis, enabling rapid and specific diagnosis of bovine tuberculosis.

Benefits of technology

The method achieves high sensitivity and specificity for detecting Mycobacterium bovis, suitable for rapid diagnosis in cattle farms and slaughterhouses, reducing the need for costly and time-consuming biosafety facilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024061131945-PAT00001_ABST
    Figure 112024061131945-PAT00001_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for detecting IS1081 based on gene editing tools, and a method and kit for diagnosing bovine tuberculosis using the same. More specifically, the invention relates to a CRISPR / Cas system, primers, and probes for detecting the IS1081 gene of Mycobacterium bovis (M. bovis), and a method and kit for diagnosing bovine tuberculosis using the same. Since the method and kit for diagnosing bovine tuberculosis according to the present invention can effectively detect bovine tuberculosis with high sensitivity and specificity, they are useful for the rapid diagnosis and utilization research of bovine tuberculosis prior to confirmation of suspected animals at slaughterhouses and testing laboratories and bacterial culture.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a composition for detecting IS1081 based on gene editing tools, and a method and kit for diagnosing bovine tuberculosis using the same, and more specifically, to Mycobacterium bovis ( Mycobacterium bovis , M . bovis The present invention relates to a CRISPR / Cas system, primers, and probes for detecting the IS1081 gene of ), and a method and kit for diagnosing bovine tuberculosis using the same. Background Technology

[0003] Bovine tuberculosis is a wasting disease of cattle characterized by chronic debilitation over several months to years, and tuberculosis bacteria ( Mycobacterium tuberculosis It is caused by infection with the complex (MTC), and among them, Mycobacterium bovis ( M . bovis Infection of ) is a typical example. It is a legal Class 2 infectious animal disease and a zoonotic disease that affects most mammals, and among livestock, it is primarily a problem for cattle.

[0004] It is transmitted orally through contaminated feed, water, or milk, and droplet infection, airborne transmission, and intrauterine infection are also possible. There are no specific clinical symptoms externally, but it causes coughing or difficulty breathing, swelling of the superficial lymph nodes, swelling of the udder without fever, and a decrease or cessation of milk secretion. Tuberculous nodules primarily form in the respiratory system, such as the lungs and pleura, but also in the liver, spleen, peritoneum, and lymph nodes; the center of the nodule undergoes necrosis followed by caseosis and calcification over time. In cattle, small, lustrous, pearl-shaped tuberculous nodules are commonly observed in the pleura and peritoneum, which is why it is also called pearl disease.

[0005] These diagnostic methods for bovine tuberculosis primarily utilize cellular immune responses, and the World Animal Health Organization (WOAH) designates Mycobacterium bovis ( M. Bovis Skin tests using PPD-B (Purified Protein Derivatives-Bovine), a protein antigen extracted from the plant, are recognized, and gamma interferon (IFN-γassay) is also recognized as an auxiliary diagnostic method (Korean Patent Publication No. 10-2011-0052295). In addition, there are methods such as antibody ELISA, isolation and identification of tuberculosis bacteria to identify the causative agent, and PCR. However, isolation and identification of tuberculosis bacteria has the disadvantage of requiring facilities of Biosafety Level 3 or higher and consuming a long time and cost to reach a diagnosis. Therefore, for the management of tuberculosis in cattle farms in Korea, skin tests or gamma interferon (IFN-γassay) are mainly used for live cattle, while PCR, which has high sensitivity and convenience, is mainly used for cattle shipped to slaughterhouses when tissue suspected of tuberculosis infection is found through slaughter inspection.

[0006] One such method is Mycobacterium bovis ( M. Bovis To confirm ) insertion sequences (IS) specific to Mycobacterium tuberculosis, such as IS6110, IS1081, and IS1561, are used as gene amplification sites via PCR (Zumarraga et al., 2005, J Vet Diagn Invest 17: pp.232-238; Taylor et al., 2007, BMC Vet Res 3:12).

[0007] Also, tuberculosis bacteria ( Mycobacterium tuberculosis , M. tuberculosis Based on reports that Mycobacterium bovis ( possesses a 12.7 kb gene segment inserted only in it, and that this 12.7 kb gene segment causes differences in pathogenicity and host range, M . bovis A PCR method capable of differentiating between ) and has also been developed (Bakshi et al., 2005, Vet Microbiol 109: pp. 211-216).

[0008] Korean Patent No. 10-1323857 describes a PCR composition for detecting bovine tuberculosis bacteria, a kit for diagnosing bovine tuberculosis containing the same, and a method for diagnosing bovine tuberculosis using the same, and Korean Patent No. 10-2123621 describes a method for detecting non-tuberculosis bacteria, tuberculosis bacteria, and multidrug-resistant tuberculosis bacteria using Real-time PCR and melting temperature measurement.

[0009] Meanwhile, the CRISPR (clustered regularly interspaced short palindromic repeats) / Cas (CRISPR-associated) system, which is an immune system used by microorganisms to respond to viruses, was introduced into heterologous cells in 2012 to selectively cut target nucleotide sequences. It was discovered that this could be used to edit the genomes of various cells ranging from microorganisms to human cells, and as a gene editing technology, it is expected to be utilized more efficiently and conveniently in biological improvement (Jinek et al., Science, 337(6096): 816-821, 2012).

[0010] Recently, rapid diagnostic techniques with high field applicability using CRISPR and Cas systems have been introduced (Yuan, J. et al., Nature communications Vol. 10(1), pp. 1-9, 2019). Lachnospiraceae ( Lachnospiraceae Cas12a from bacteria can recognize target DNA using a guide RNA (gRNA) complementary to the target DNA sequence containing a T nucleotide-rich PAM (protospacer-adjacent motif). It is known that Cas12a is effectively activated when it has a 5'-TTTN-3' structured PAM site at its 5' end (Paul B, et al., Biomed J. Vol. 43(1) pp. 8-17, 2020).

[0011] Cas12a is activated after recognizing target DNA and nonspecifically cleaves single-stranded DNA (ssDNA) (Chen JS et al., Science Vol.360(6387), pp. 436-439, 2018). Based on the trans-cleavage activity of Cas12a and isothermal nucleic acid amplification techniques, novel molecular diagnostic methods named DETECTR (DNA endonuclease-targeted CRISPR trans reporter) and HOLMES (one-hour low-cost multipurpose highly efficient system) have been developed (Chen JS et al., Science Vol.360(6387), pp. 436-439, 2018; Li SY et al., Cell Discov Vol. 4, 20, 2018), and have been successfully applied to the diagnosis of viral infections including SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), HPV (human papilloma virus), IAV (influenza A virus), and IBV (influenza virus) (Broughton et al. Nat Biotechnol. Vol. 38(7), pp. 870-874, 2020; Chen JS et al., Science Vol.360(6387), pp. 436-439, 2018; Park et al., Biosensors, Vol. 11(3), 88, 2021).

[0012] HOLMES has the advantage of being able to identify single nucleotide variants and distinguish them even if variants exist in the PAM sequence, because it applies the CRISPR / Cas system after pre-amplification using PCR (Li SY et al., Cell Discov Vol. 4, 20, 2018). This high specificity is made possible through the design of crRNA (CRISPR RNA) with a spacer consisting of 16-17 nucleotides.

[0013] Accordingly, the inventors of the present invention provide a CRISPR / Cas12a-based gene detection method for Mycobacterium bovis ( M . bovis As a result of efforts to apply it to the detection of ) Mycobacterium bovis ( M . bovis When the ) gene is amplified using primers, and then analyzed by introducing Cas12a protein, gene-specific guide RNA (gRNA), and probes, Mycobacterium bovis ( M . bovis It was confirmed that ) can be detected, and the present invention was completed. The problem to be solved

[0015] The objective of the present invention is Mycobacterium bovis ( M . bovis The purpose is to provide a detection composition capable of detecting ).

[0016] Another objective of the present invention is to use the above-mentioned detection composition for Mycobacterium bovis ( M . bovis The purpose is to provide a diagnostic method and kit for bovine tuberculosis through detection. means of solving the problem

[0018] To achieve the above objective, the present invention comprises: (a) a primer pair capable of amplifying the IS1081 gene; (b) a guide RNA (gRNA) that specifically recognizes the IS1081 gene represented by the nucleotide sequence of SEQ ID NO. 1; (c) a Cas(CRISPR-associated protein) 12a protein; and (d) a single-stranded DNA (ssDNA) probe; Mycobacterium bovis ( M. Bovis ) provides a composition for detection.

[0019] The present invention also provides a diagnostic kit for bovine tuberculosis comprising the above composition.

[0020] The present invention also provides a method for diagnosing bovine tuberculosis comprising the following steps:

[0021] (a) a step of isolating DNA from a sample and obtaining an amplification product of the IS1081 gene using a primer pair capable of amplifying the IS1081 gene;

[0022] (b) a guide RNA (gRNA) that specifically recognizes the IS1081 gene represented by the nucleotide sequence of SEQ ID NO. 1 to the amplification product obtained in step (a); Cas(CRISPR-associated protein) 12a protein; and single-stranded DNA (ssDNA) probe;

[0023] A step of performing molecular diagnosis by gene scissors by adding; and

[0024] (c) Mycobacterium bovis used in the above specimen ( M . bovis A step to determine the existence of ). Effects of the invention

[0026] The kit and method for diagnosing bovine tuberculosis according to the present invention can effectively detect bovine tuberculosis with high sensitivity and specificity, so they are useful for rapid diagnosis and utilization research of bovine tuberculosis prior to confirmation of suspected animals at slaughterhouses and testing laboratories and bacterial culture. Brief explanation of the drawing

[0028] FIG. 1 shows the results of a specificity test in various strains of a detection method according to one embodiment of the present invention, where (A) is a tuberculosis bacterial group [ Mycobacteria tuberculosis (B) is a fluorescence image of the standard strain of the [MTC] complex [MTC], (B) is a fluorescence image of the standard strain of Nontuberculous mycobacteria [NTM], and (C) is a fluorescence image of the Mycobacterium avium complex [ Mycobacteria avium As fluorescence images of the standard strains [complex (MAC)], the strains for each lane are as listed in Table 6. Figure 2 shows the results of measuring fluorescence intensity in the specificity test results for various strains of the detection method according to one embodiment of the present invention, and the strains for each lane are as listed in Table 7. FIG. 3 shows an electrophoretic photograph (A) and a UV fluorescence image (B) representing the results of a sensitivity test in a standard strain of a detection method according to an embodiment of the present invention, with each lane as described in Table 8. FIG. 4 is a fluorescence image confirming the performance of the detection method according to one embodiment of the present invention in a positive tissue sample, and the samples for each lane are as described in Table 9. FIG. 5 is a fluorescence image confirming the performance of the detection method according to one embodiment of the present invention in a negative tissue sample, and the samples for each lane are as described in Table 10. Specific details for implementing the invention

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which this invention pertains. In general, the nomenclature used herein and the experimental methods described below are well known and commonly used in the art.

[0030] In the present invention, Mycobacterium bovis ( M . bovis ) When the gene IS1081 is amplified using primers and then analyzed using a gene editing system, Mycobacterium bovis ( M . bovis We intended to confirm that ) can be detected.

[0031] That is, in one embodiment of the present invention, Mycobacterium bovis ( M . bovis ) If a guide RNA (gRNA) that specifically binds to the gene IS1081 is designed and used to perform molecular diagnosis, Mycobacterium bovis ( M . bovis It was confirmed that ) can be detected (Fig. 1).

[0032] Accordingly, in one aspect, the present invention,

[0033] (a) A primer pair capable of amplifying the IS1081 gene;

[0034] (b) Guide RNA (gRNA) that specifically recognizes the IS1081 gene represented by the nucleotide sequence of SEQ ID NO. 1;

[0035] (c) Cas(CRISPR-associated protein) 12a protein; and

[0036] (d) single-stranded DNA (ssDNA) probe;

[0037] Mycobacterium bovis (including Mycobacterium bovis, M. bovis This relates to a composition for detection.

[0039] In the present invention, the primer pair may be used without limitation as long as it is a forward primer and a corresponding reverse primer pair that can bind to a guide RNA (gRNA) including a PAM (protospacer-adjacent motif) sequence, and preferably, the primer pair may be characterized as being composed of the forward primer of SEQ ID NO. 2 and the reverse primer of SEQ ID NO. 3, but is not limited thereto.

[0041] In the present invention, the IS1081 gene to which the guide RNA (gRNA) binds may be characterized by being represented by the nucleotide sequence of SEQ ID NO. 1 below, but is not limited thereto.

[0042] Sequence No. 1: IS1081 Sequence

[0043]

[0045] In the present invention, the guide RNA (gRNA) can be used without limitation as long as it is a sequence capable of binding to the IS1081 gene, and preferably, it may be characterized as being represented by the nucleotide sequence of SEQ ID NO. 4, but is not limited thereto.

[0046] Typically, a gene editing system (CRISPR / Cas system) consists of a Cas protein, crRNA (CRISPR RNA), and tracrRNA (trans-activating CRISPR RNA). Since the crRNA contains a spacer that binds to a target site and an RNA sequence that can hybridize with tracrRNA, it is characterized by forming an RNA-RNA complex through a step of preferential hybridization with tracrRNA before forming a complex with the Cas protein. Additionally, the crRNA and tracrRNA can be artificially fused to induce the formation of a complex with the Cas protein in a single-stranded state.

[0047] The term 'guide RNA (gRNA)' in the present invention typically includes crRNA and tracrRNA, and specifically is characterized by being a double strand or a single strand formed by the fusion of the two RNAs, comprising RNA containing a spacer or guide sequence that binds to a target site (sequence) and RNA that binds to a Cas protein. Accordingly, the term 'guide RNA (gRNA)' may be used interchangeably with 'single strand guide RNA', 'chimeric RNA', 'chimeric guide RNA', and 'synthetic guide RNA'. Furthermore, the term 'guide RNA (gRNA)' may be interpreted to include all RNAs that constitute a complex characterized by binding to a Cas protein (or endonuclease) to bind to a target site, or binding to and cleaving said target site.

[0048] The above 'fusion' is a molecule in which two or more subunit molecules are preferably covalently bonded. The subunit molecules may be molecules of the same chemical type or molecules of different chemical types. The fusion of crRNA and tracrRNA in the above guide RNA (gRNA) is characterized by a state in which the backbones are connected by phosphorylation bonds rather than hydrogen bonds, and the structure is composed of a single strand.

[0049] In the present invention, the term 'guide sequence' refers to an RNA sequence having a length of 30 bp or less at the 5' end of a guide RNA (gRNA) and having characteristics complementary to a target site, and may be used interchangeably with spacer or spacer sequence. Typically, any sequence that does not participate in binding with the Cas protein in a Cas protein / guide RNA (gRNA) complex but acts to bind complementarily to the target site can be interpreted as corresponding to the above term.

[0050] In the present invention, the guide RNA (gRNA) may be composed of (a) crRNA and tracrRNA containing a guide sequence, (b) a fusion of crRNA and tracrRNA containing a guide sequence (chimeric guide RNA), or (c) crRNA containing a guide sequence, and more preferably, may be characterized as crRNA containing a guide sequence, but is not limited thereto.

[0051] The guide RNA (gRNA) of the present invention may have modifications applied to the nucleic acid backbone or bases: for backbone modification, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, 3'-alkylene phosphonates, 5'-alkylene phosphonates, chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate, aminoalkylphosphoramidates, phosphorodiamidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, boranophosphate, etc. may be used, and for sugar molecule residue modification, 2′2′′′, etc. may be used, but is not limited thereto.In addition, regarding base modification, instead of conventional purines and pyrimidines, 5-methylcytosine (5meC), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, 2-pyridone, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, 5-propynyl uracil, 6-azo uracil, pseudouracil, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, It may be 3-deazaadenine, phenoxazine cytidine, phenothiazine cytidine, carbazole cytidine, pyridoindole cytidine, etc., but is not limited to these.

[0053] The Cas protein in the present invention is Suterella ( Sutterella ), Legionella( Legionella ), Treponema( Treponema ), Pirifactor( Filifactor ), Eubacterium ( Eubacterium ), Streptococcus( Streptococcus ), Lactobacillus( Lactobacillus ), Mycoplasma( Mycoplasma ), Bacteroides( Bacteroides ), Flavivola( Flaviivola ), Flavobacterium( Flavobacterium ), azospirillum( Azospirillum ), Gluconacetobacter( Gluconacetobacter ), Neisseria( Neisseria ), Roseburia( Roseburia ), Fabivacurum( Parvibaculum ), Staphylococcus( Staphylococcus ), Nitratifractor( Nitratifractor ), Corynebacterium( Corynebacterium ), Campylobacter( Campylobacter ) and Lachnospiraceae( Lachnospiraceae It is derived from a microbial genus containing an ortholog of a Cas protein selected from the group consisting of ), and may be one or more Cas proteins, either simply isolated or recombinant, and specifically, Lachnospiraceae ( Lachnospiraceae It may be of origin, but is not limited to this.

[0054] The Cas protein in the present invention binds to guide RNA (gRNA) to form a complex, recognizes the PAM sequence present on the sequence of the target gene to guide the gene scissors system to the target gene, identifies the target gene through complementary binding between the guide sequence of the guide RNA (gRNA) and the target site, and finally exhibits nucleic acid cleavage activity having the characteristics of a double strand break through the active site, and in the case of Cas 12a, induces collateral cleavage of surrounding single-stranded DNA (ssDNA) that is not the target.

[0055] Information on the gene and protein of the Cas protein is available from GenBank at the National Center for Biotechnology Information (NCBI).

[0057] In the present invention, the DNA probe may have a reporter and a fluorescent substance of a quencher capable of quenching reporter fluorescence attached to both ends, and may include an intercalating fluorescent substance. The reporter may be one or more selected from the group consisting of FAM (6-carboxyfluorescein), HEX (Hexachlorofluorescein), Texas red, JOE (4-5-Dichlorocarboxyfluorescein), TAMRA (6-carboxytetramethyl-rhodamine), CY5, CY3, or Alexa680, and the quencher may be one or more selected from the group consisting of TAMRA (6-carboxytetramethyl-rhodamine), BHQ1 (Black Hole Quencher 1), BHQ2 (Black Hole Quencher 2), BHQ3 (Black Hole Quencher 3), and Dabcyl, but is not limited thereto.

[0058] The above intercalating fluorescent material is acridine homodimer and its derivatives, acridine orange and its derivatives, 7-aminoactinomycin D (7-AAD) and its derivatives, actinomycin D and its derivatives, ACMA (9-amino-6-chloro-2-methoxyacridine) and its derivatives, DAPI and its derivatives, dihydroethidium and its derivatives, ethidium bromide and its derivatives, ethidium homodimer-1 (EthD-1) and its derivatives, ethidium homodimer-2 (EthD-2) and its derivatives, ethidium monoazide and its derivatives, It may be selected from the group consisting of hexidium iodide and derivatives thereof, bisbenzimide (Hoechst 33258) and derivatives thereof, Hoechst 33342 and derivatives thereof, Hoechst 34580 and derivatives thereof, hydroxystilbamidine and derivatives thereof, LDS 751 and derivatives thereof, propidium iodide (PI) and derivatives thereof, and Cy-dyes derivatives.

[0059] In the present invention, a DNA probe containing a reporter and a quencher remains in a state where the fluorescent signal is quenched in a single-stranded state, but when cleaved by Cas12a, a fluorescent signal is generated, and the presence or absence of a target nucleic acid can be detected through the analysis of this fluorescent signal.

[0060] The term "probe" in the present invention refers to a nucleic acid fragment ranging from a few bases to several hundred bases in length that can form a specific binding with a gene or mRNA. It may be produced in the form of an oligonucleotide probe, a single-stranded DNA (ssDNA) probe, a double-stranded DNA probe, an RNA probe, a Peptide Nucleic Acid (PNA) probe, a Locked Nucleic Acid (LNA) probe, etc., and may be labeled for easier detection, but is not particularly limited thereto.

[0062] In the present invention, the single-stranded DNA (ssDNA) probe may be characterized by being cleaved by a Cas12a protein that is activated in the presence of the IS1081 gene, and preferably represented by the nucleotide sequence of SEQ ID NO. 5, but is not limited thereto.

[0064] In another aspect, the present invention relates to a kit for diagnosing bovine tuberculosis comprising the above composition.

[0065] In the present invention, the kit may optionally include reagents necessary for carrying out nucleic acid amplification reactions (e.g., polymerase chain reaction), such as a buffer, DNA polymerase, DNA polymerase cofactor, and deoxyribonucleotide-5-triphosphate (dNTP). Optionally, the kit of the present invention may also include various oligonucleotide molecules, reverse transcriptase, various buffers and reagents, and antibodies that inhibit DNA polymerase activity. Additionally, the optimal amount of reagent used in a specific reaction of the kit can be easily determined by a person skilled in the art who has acquired the details described herein. Typically, the equipment of the present invention may be manufactured as a separate package or compartment containing the aforementioned components.

[0066] In one embodiment, the kit may include a compartmentalized carrier means for holding a sample, a container containing a reagent, and a container containing a primer or probe.

[0067] The above-mentioned carrier means is suitable for containing one or more containers, such as bottles or tubes, and each container contains independent components used in the method of the present invention. In the specification of the present invention, a person skilled in the art can easily dispense the necessary formulation in the container.

[0068] Additionally, the kit may include a guide. The guide is a printed document explaining the use of the kit, for example, the method of preparing the buffer solution, the presented reaction conditions, etc. The guide includes instructions in the form of a pamphlet or leaflet, a label attached to the kit, and on the surface of a package containing the kit. Furthermore, the guide includes information disclosed or provided through electronic media, such as the Internet.

[0070] In another aspect, the present invention relates to a method for diagnosing bovine tuberculosis comprising the following steps:

[0071] (a) a step of isolating DNA from a sample and obtaining an amplification product of the IS1081 gene using a primer pair capable of amplifying the IS1081 gene;

[0072] (b) a guide RNA (gRNA) that specifically recognizes the IS1081 gene represented by the nucleotide sequence of SEQ ID NO. 1 to the amplification product obtained in step (a); Cas(CRISPR-associated protein) 12a protein; and single-stranded DNA (ssDNA) probe;

[0073] A step of performing molecular diagnosis by gene scissors by adding; and

[0074] (c) Mycobacterium bovis in the above specimen ( M. Bovis A step to determine the existence of ).

[0075] In the present invention, step (b) may be characterized by including detection of a target site among the amplification products by the guide RNA (gRNA), activation of Cas12a, and cleavage of a single-stranded DNA (ssDNA) probe by the activated Cas12a.

[0076] In the present invention, step (c) may be characterized by detecting and confirming, by fluorescence analysis, that when the IS1081 gene is present, the single-stranded DNA (ssDNA) probe is cleaved by the activated Cas12a protein and exhibits fluorescence, and when the IS1081 gene is not present, the single-stranded DNA (ssDNA) probe is not cleaved and does not exhibit fluorescence, but is not limited thereto.

[0078] In the present invention, the sample is derived from a specimen to be diagnosed with bovine tuberculosis and comprises DNA or RNA molecules, and said molecules may be in a double-stranded or single-stranded form. When the nucleic acid as the initial material is double-stranded, it is preferable to convert the two strands into single strands or partially single strands. Methods known for separating strands include, but are not limited to, heat, alkali, formamide, urea, and glycoxal treatment, enzymatic methods (e.g., helicase action), and binding proteins. For example, strand separation can be achieved by heat treatment at a temperature of 80°C to 105°C.

[0079] In the present invention, the sample may be blood, secretions, feces, cells, tissues, organs, or parts of the body, but is not limited thereto.

[0080] In the present invention, the amplification of step (a) may be characterized by being performed by a polymerase chain reaction (PCR) method, but is not limited thereto.

[0081] In the present invention, the amplification of step (a) may be characterized by being performed using a real-time polymerase chain reaction (real-time PCR) method, but is not limited thereto.

[0083] Examples

[0084] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0086] Example 1. Mycobacterium bovis ( M . bovis Design of primers, guide RNA (gRNA), and single-stranded DNA (ssDNA) probes for the detection of

[0087] Mycobacterium bovis ( M. BovisTo confirm the presence of infection, for the guide RNA (gRNA) for detecting Mycobacterium bovis, the IS1081 sequence (GenBank accession no. AL123456.3) registered in the NCBI Genbank was analyzed to detect Mycobacterium bovis ( M. Bovis A guide RNA (gRNA) capable of recognizing the PAM sequence (TTTN) of the IS1081 region was designed, and for the primers, a primer set capable of specifically amplifying the IS1081 gene containing the recognition site of the guide RNA (gRNA) was designed, and a single-stranded DNA (ssDNA) probe was constructed to be cleaved by the activated Cas12a, which binds to the amplification product of the guide RNA (gRNA) (Table 1).

[0088] Mycobacterium bovis ( M . bovis Guide RNA (gRNA), primer, and probe sequences used for IS1081 gene detection Sequence number name order amplification product length (bp) 2 IS1081_1F TACCGCCACCGTGATTTC 199 3 IS1081_1R CACCAAGTGTTTCGACCA 4 IS1081_guide RNA GACACCCGTGCCGCAACCATCGA 5 ssDNA_probe CCCCCCCC

[0089] It was produced by commissioning and used, and the guide RNA (gRNA) was commissioned to IDT (Iowa, USA).

[0091] Example 2. Mycobacterium bovis ( M . bovis ) Analysis of detection results

[0092] 2-1. Generation of Amplification Products

[0093] Maxwell from various strains ®DNA was isolated using the RSC Pure Food GMO and Authentication kit (Promega, Wisconsin, USA), and a PCR composition was prepared according to the composition in Table 2 below. A PCR reaction was then performed using a C1000 Touch Thermal Cycler (Bio-Rad, California, USA) under the conditions in Table 3.

[0094] PCR composition PCR components Total DNA: 5 µl Forward primer (10 pmol / ㎕): 1 ㎕ Reverse Primer (10 pmol / ㎕): 1 ㎕ Distilled Water (DW): 3 µL Master mix 쪌 : 10 ㎕ Total: 20 µl

[0095] 쪌 Master mix: GoTaq®Star Master Mixes (Promega, Wisconsin, USA)

[0096] PCR reaction steps PCR condition Step Temperature (°C) Time 1. Pre-denaturation 94 5 min 2. Denaturation 94 30 seconds 3. Annealing 58 1 minute 4. Extension 72 30 seconds Go to step 2, 37 cycles 5. Final extension 72 5 minutes 6. Storage 12 ∞

[0097] 2-2. CRISPR / Cas molecular mechanism

[0098] After confirming the amplification product obtained in Example 2-1 through electrophoresis, the probe was prepared with the composition of Table 4 below, and the guide RNA (gRNA) of Table 1, Cas12a, and single-stranded DNA (ssDNA) probe were added to perform the probe cleavage reaction under the conditions of Table 5. Then, fluorescence was confirmed using UV light, and the presence of the cleavage product was determined by measuring the fluorescence using the CFX96™ System (Bio-Rad, California, USA).

[0099] CRISPR / Cas molecular diagnostic composition CRISPR / Cas Components Lb Cas12a*(100 nM): 2 ㎕ gRNA (100 nM): 2 ㎕ PCR product: 5 ㎕ Buffer (10x) 쪍 : 2 ㎕ ssDNA (500 nM) § : 2 ㎕ DW: 7㎕ Total: 20 ㎕

[0100] *: Lb Cas12a: Alt-R™Cas12a(Cpf1) Ultra, 500 ug (IDT, Iowa, USA) 쪍 : Buffer: NEBuffer™ (New England Biolabs, Massachusetts, England)

[0101] §: ssDNA: 5'HEX-Sequence No. 5-3'BHQ1 (Macrogen, Daejeon, Korea)

[0102] CRISPR / Cas molecular diagnostic response Step Temperature (℃) Time incubation 37 1 hour

[0103] 2-3. result

[0104] Tuberculosis bacteria group[ Mycobacterium tuberculosis complex (MTC)] standard strain, Nontuberculous mycobacteria (NTM) standard strain and Mycobacterium avium complex [ Avian mycobacteria As a result of performing the methods of Examples 2-1 and 2-2 using the primer set of SEQ ID NOs. 2 and 3 and the guide RNA (gRNA) of SEQ ID NO. 4 with a standard strain [complex (MAC)], it was confirmed that the guide RNA (gRNA) and primer set according to the present invention can clearly identify the standard strain, as described in FIG. 1. The strains for each lane in FIG. 1 are as shown in Table 6 below.

[0105] Composition of each reference strain Lane MTC NTM MAC 1 Mycobacterium bovis AN5 (ATCC 35726) Mycobacterium fortuitum (KCTC 25618) Mycobacterium of birds subsp. of birds (ATCC 35716) 2 Mycobacterium bovis BCG (ATCC 35734) Mycobacterium gordonii (KCTC 9513) Mycobacterium intracellular (KCTC 9514) 3 Mycobacterium tuberculosis (CDC1551) Mycobacterium kansasii (KCTC 9515) Mycobacterium of birds subsp. their own (ATCC 19978) 4 Mycobacterium tuberculosis (NCCP 15985) Mycobacterium phlei (KCTC 2192) Mycobacterium avium subsp. paratuberculosis (ATCC 19851) 5 Mycobacterium tuberculosis (NCCP 15986) Mycobacterium smegmatis (KCTC 9108) Mycobacterium avium subsp. paratuberculosis (ATCC 19698) 6 Mycobacterium tuberculosis H37Ra (ATCC 25177) Mycobacterium abscessus (= Mycobacterium abscessus (KCTC 19621) Negative control (DW) 7 Mycobacterium tuberculosis H37Rv (ATCC 25618) Mycobacterium chelonae (= Mycobacteroids chelones (KCTC 9505) 8 Negative control (DW) Mycobacterium mucogenicum (= Mycolicibacterium mucogenicum (KCTC 19088)

[0107] Example 3. Kita 균주기들 대한 소성도 test

[0108] Mycobacterium bovis ( M. ox To verify the specificity of ) against DNA target pathogens and other strains, a test was performed using various strains commonly found in cattle in the same manner as in Example 2.

[0109] As a result, as described in FIG. 2, Mycobacterium bovis ( M. ox It was confirmed that the specificity of the kit produced in the present invention is very high by confirming that no fluorescence was detected in any strain except the standard strain.

[0110] The lane-specific strains used in Example 3 and Figure 2 are as shown in Table 7 below.

[0111] strains used Lane 균주 Lane 균주 1 Acinetobacter baumannii (KCCM 35453) 13 Pseudomonas aeruginosa (ATCC 27853) 2 Bacillus cereus (KCTC 1094) 14 Salmonella Enteritidis (ATCC 13076) 3 Clostridium perfringens (KCCM 35453) 15 Salmonella Typhimurium (ATCC 14028) 4 Clostridium difficile (KVCC Ba1100001) 16 Staphylococcus epidermidis (ATCC 1228) 5 Enterococcus faecalis (ATCC 29212) 17 Staphylococcus aureus (ATCC 25923) 6 Enterococcus faecium (ATCC 51558) 18 Staphylococcus pseudintermedius (ATCC 49051) 7 Escherichia coli (ATCC 25922) 19 Staphylococcus intermedius (KCTC 3344) 8 Escherichia coli O157:H7 (ATCC 43894) 20 Streptococcus dysgalactiae (ATCC 12388) 9 Klebsiella pneumoniae (ATCC 700603) 21 Yersinia enterocolitica (ATCC 9610) 10 Listeria monocytogenes (ATCC 19115) 22 Negative control (DW) 11 Mannheimia haemolytica (ATCC 33396) 23 Positive control ( M. Bovis AN5) 12 Proteus mirabilis (ATCC 22906)

[0113] Example 4. Sensitivity test for standard strains

[0114] 4-1. Verification of sensitivity based on CRISPR / Cas method

[0115] In order to determine the minimum pathogen DNA concentration that the primers of the kit prepared in the present invention can amplify in positive tissue, a sensitivity test of the primers was performed using the method of Example 2.

[0116] In other words, Mycobacterium bovis ( M. Bovis ) standard strain M. Bovis After diluting AN5 DNA (50 ng / ul) to the concentrations in Table 8, a sensitivity test was performed in the same manner as in Example 2.

[0117] As a result, as shown in FIG. 3, the kit produced in the present invention is 5.0x10 -6 It was confirmed that strain DNA diluted to ng / ul can be detected.

[0118] Dilution ratio per lane Lane density Lane density M Marker*, 100 bp 9 5.0x10 -8 of / of 1 5.0x10 ng / ul 10 5.0x10 -9 of / of 2 5.0x10 -1 of / of 11 5.0x10 -10 of / of 3 5.0x10 -2 of / of 12 5.0x10 -11 of / of 4 5.0x10 -3 of / of 13 5.0x10 -12 of / of 5 5.0x10 -4 of / of 14 5.0x10 -13 of / of 6 5.0x10 -5 of / of 15 5.0x10 -14 of / of 7 5.0x10 -6 of / of 16 Negative control (DW) 8 5.0x10 -7 of / of M Marker, 100 bp

[0119] * : Marker: 100 bp DNA ladder marker (Enzynomics, Daejeon, Korea)

[0121] Example 5. Verification of performance on tissue samples

[0122] 5-1. Performance Verification Based on CRISPR / Cas Method

[0123] In order to verify the performance of the kit produced in the present invention on actual tissue samples, Mycobacterium bovis (possessed by this institution) M. Bovis In negative and positive tissues, molecular diagnosis was performed using the method of Example 2.

[0124] In the case of benign tissue, Mycobacterium bovis (in intradermal test, gamma interferon assay (IFN-γassay) and bacterial isolation and identification) M. Bovis DNA extracted from the tissue of a cow that was confirmed to be positive for bovine tuberculosis, and DNA extracted from the tissue of a cow that was determined to be negative for bovine tuberculosis in the case of negative tissues using the skin test, gamma interferon test (IFN-γassay) and PCR test.

[0125] As a result, it was confirmed that the kit produced in the present invention detects all positive samples as described in Fig. 4, and does not show a fluorescence reaction in all negative samples as described in Fig. 5.

[0126] Sample names by lane for positive samples Lane Sample Lane Sample 1 Benign tissue 1 7 Benign tissue 7 2 Benign tissue 2 8 Benign tissue 8 3 Benign tissue 3 9 Benign tissue 9 4 Benign tissue 4 10 Benign tissue 10 5 Benign tissue 5 11 Negative control (DW) 6 Benign tissue 6 12 Positive control ( M. Bovis AN5)

[0128] Sample names by lane for voice samples Lane Sample Lane Sample Lane Sample 1 Voice tissue_1 11 Voice tissue_11 21 Voice tissue_21 2 Voice tissue_2 12 Voice tissue_12 22 Voice tissue_22 3 Voice tissue_3 13 Voice tissue_13 23 Voice tissue_23 4 Voice tissue_4 14 Voice tissue_14 24 Voice tissue_24 5 Voice tissue_5 15 Voice tissue_15 25 Voice tissue_25 6 Voice tissue_6 16 Voice tissue_16 26 Voice tissue_26 7 Voice tissue_7 17 Voice tissue_17 27 Voice tissue_27 8 Voice tissue_8 18 Voice tissue_18 28 Voice tissue_28 9 Voice tissue_9 19 Voice tissue_19 29 Negative control (DW) 10 Voice tissue_10 20 Voice tissue_20 30 Positive control ( M. Bovis AN5)

[0130] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

Claim 1 (a) a primer pair capable of amplifying the IS1081 gene, comprising a forward primer of SEQ ID NO. 2 and a reverse primer of SEQ ID NO. 3; (b) a guide RNA (gRNA) that specifically recognizes the IS1081 gene represented by the nucleotide sequence of SEQ ID NO. 1; (c) a Cas(CRISPR-associated protein) 12a protein; and (d) a single-stranded DNA (ssDNA) probe; comprising Mycobacterium bovis ( Mycobacterium bovis, M. bovis ) Composition for detection. Claim 2 delete Claim 3 In claim 1, the guide RNA (gRNA) is characterized by being represented by the nucleotide sequence of SEQ ID NO. 4, Mycobacterium bovis ( M . bovis ) Composition for detection. Claim 4 In claim 1, the single-stranded DNA (ssDNA) probe is characterized by having a reporter and a quencher bound to it, Mycobacterium bovis ( M . bovis ) Composition for detection. Claim 5 In claim 4, the reporter is characterized as being one or more selected from the group consisting of FAM (6-carboxyfluorescein), HEX (Hexachlorofluorescein), Texas red, JOE (4-5-Dichlorocarboxyfluorescein), TAMRA (6-carboxytetramethyl-rhodamine), CY5, CY3, or Alexa680, Mycobacterium bovis ( M . bovis ) Composition for detection. Claim 6 In claim 4, the quencher is characterized as being one or more selected from the group consisting of TAMRA (6-carboxytetramethyl-rhodamine), BHQ1 (Black Hole Quencher 1), BHQ2 (Black Hole Quencher 2), BHQ3 (Black Hole Quencher 3), and Dabcyl, Mycobacterium bovis ( M . bovis ) Composition for detection. Claim 7 In claim 1, the single-stranded DNA (ssDNA) probe is characterized by being cleaved by a Cas12a protein that is activated in the presence of the IS1081 gene, Mycobacterium bovis ( M . bovis ) Composition for detection. Claim 8 In claim 1, the single-stranded DNA (ssDNA) probe is characterized by being represented by the nucleotide sequence of SEQ ID NO. 5, Mycobacterium bovis ( M . bovis ) Composition for detection. Claim 9 A diagnostic kit for bovine tuberculosis comprising the composition of claim 1. Claim 10 A method for diagnosing bovine tuberculosis comprising the following steps: (a) isolating DNA from a specimen and obtaining an amplification product of the IS1081 gene using a primer pair composed of a forward primer of SEQ ID NO. 2 and a reverse primer of SEQ ID NO. 3, capable of amplifying the IS1081 gene; (b) adding a guide RNA (gRNA) that specifically recognizes the IS1081 gene represented by the nucleotide sequence of SEQ ID NO. 1; a Cas(CRISPR-associated protein) 12a protein; and a single-stranded DNA (ssDNA) probe to the amplification product obtained in step (a), and performing molecular diagnosis by gene scissors; and (c) Mycobacterium bovis ( M . bovis A step to determine the existence of ). Claim 11 A method for diagnosing bovine tuberculosis according to claim 10, wherein step (b) comprises detection of a target site among the amplification products by the guide RNA (gRNA), activation of Cas12a, and cleavage of a single-stranded DNA (ssDNA) probe by the activated Cas12a. Claim 12 A method for diagnosing bovine tuberculosis according to claim 10, wherein step (c) is characterized in that when the IS1081 gene is present, the single-stranded DNA (ssDNA) probe is cleaved by the activated Cas12a protein to produce fluorescence, and when the IS1081 gene is not present, the single-stranded DNA (ssDNA) probe is not cleaved and fluorescence does not appear.

Citation Information

Patent Citations

  • Method and Kit for Diagnosing Bovine tuberculosis using PNA

    KR1020230057778A

  • CRISPR-Cas12a-based detection of severe fever with thrombocytopenia syndrome virus

    KR1020230062112A